LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)
Retrieved on:
Tuesday, December 6, 2022
Pharmaceutical, Health, Clinical Trials, Janus, Leo Pharma, Immune system, DELTA, Patient, Prevalence, Science, DKK, JAK, CHE, LEO, Research, Hyperkeratosis, Disease, Pain, Fissure, Quality of life, Erythema, Week, Itch, Hand eczema, HE, Skin, Safety, JT, Edema, Dermatology, Pharmaceutical industry, Silviculture
LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 1 trial.
Key Points:
- LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 1 trial.
- DELTA 1 is the first of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- In addition to the DELTA 1 trial, delgocitinib cream is also being investigated in the second pivotal trial DELTA 2, which is still ongoing.
- LEO Pharma is currently developing delgocitinib in a cream formulation for the treatment of moderate to severe chronic hand eczema (CHE) in adults.